Kaiser Permanente - Harbor City

Summary

Kaiser Permanente - Harbor City is a medical facility located in Harbor City, California. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer, Cancer and other specialties. Kaiser Permanente - Harbor City is involved with conducting 119 clinical trials across 265 conditions. There are 8 research doctors associated with this hospital, such as Helen H. Moon, Gary L. Buchschacher, Ashraf R. Aziz, and Eric C. McGary.

Top PIs

Clinical Trials running at Kaiser Permanente - Harbor City

Lung Cancer

Breast Cancer

Esophageal cancer

Prostate Cancer

Non-Small Cell Lung Cancer

Chronic Lymphocytic Leukemia

Breast cancer

Colon Cancer

Small intestine cancer

Small Intestinal Adenocarcinoma

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Tepotinib + Ramucirumab

for Lung Cancer

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.

Recruiting

1 award

Phase 2

4 criteria